Completed PHASE2 INTERVENTIONAL 3-arm NCT01802502

Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation (REMOVER)

Explorative PK Study Comparing 600 mg Rifampicin i.v. With 750 mg and 900 mg Rifampicin Oral in Tuberculous Meningitis Patients

Sponsor: Radboud University Medical Center

Conditions Tuberculous Meningitis

Interventions Oral rifampicin Rifampicin intravenous

Updated 6 times since 2017 Last updated: Jun 15, 2014 Started: Jun 30, 2013 Primary completion: Oct 31, 2013 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Tuberculous Meningitis and is currently completed. Radboud University Medical Center leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Mar 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Radboud University Medical Center
Universitas Padjadjaran

Data source: Universitas Padjadjaran

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bandung, Indonesia